Caribou Biosciences, Inc. (CRBU)
$
1.06
-0.10 (-9.43%)
Key metrics
Financial statements
Free cash flow per share
-1.5343
Market cap
104.2 Million
Price to sales ratio
13.7694
Debt to equity
0.1207
Current ratio
7.6278
Income quality
0.9314
Average inventory
0
ROE
-0.5570
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies aimed at treating hematologic malignancies and solid tumors both in the United States and on an international scale. The EBITDA is -$166,616,000.00 a key indicator of the company's operational profitability. The company reported selling, general, and administrative expenses of $46,457,000.00 indicating its operational overhead costs. Additionally, it reported an income before tax of -$149,114,000.00 showcasing its pre-tax profitability, with an income before tax ratio of -14.92 reflecting the pre-tax margin. The net income ratio is -14.92 which illustrates the company's profitability margin. Its lead product candidates include CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing a phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy designed for treating relapsed or refractory multiple myeloma. The company is also advancing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, and CB-020, an allogeneic CAR-NK cell therapy targeting solid tumors. Notably, Caribou has established a collaboration with AbbVie Manufacturing Management Unlimited Company to further the development of its CAR-T cell therapies. Founded in 2011 and headquartered in Berkeley, California, the company is positioned strategically in the evolving biopharmaceutical landscape. The stock is affordable at $1.16 making it suitable for budget-conscious investors. It is characterized by a high average trading volume of 1,042,284.00 indicating strong liquidity in the market. With a market capitalization of $98,584,876.00 the company is classified as a small-cap player, enhancing its visibility among investors seeking growth opportunities. Moreover, it is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Caribou Biosciences belongs to the Healthcare sector, driving innovation and growth in an ever-competitive environment.
Is Caribou Biosciences, Inc. (CRBU) a good investment?
Investing in Caribou Biosciences, Inc. (CRBU) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Caribou Biosciences, Inc. (CRBU)'s stock forecast?
Analysts predict Caribou Biosciences, Inc. stock to fluctuate between $0.66 (low) and $3 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Caribou Biosciences, Inc.'s market capitalization?
As of 2025-05-30, Caribou Biosciences, Inc.'s market cap is $98,584,876, based on 93,004,600 outstanding shares.
How does Caribou Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Caribou Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Caribou Biosciences, Inc. (CRBU) stock?
To buy Caribou Biosciences, Inc. (CRBU) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRBU. Place an order (Market, Limit, etc.).
What is the best time to invest in Caribou Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Caribou Biosciences, Inc. perform in the last earnings report?
Revenue: $9,994,000 | EPS: -$1.65 | Growth: 19.57%.
Where can I find Caribou Biosciences, Inc.'s investor relations reports?
Visit https://cariboubio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Caribou Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Caribou Biosciences, Inc. stock?
All-time high: $32.65 (2021-09-07) | All-time low: $0.66 (2025-04-07).
What are the key trends affecting Caribou Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU.
zacks.com
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.39 per share a year ago.
globenewswire.com
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU) on behalf of long-term stockholders following a class action complaint that was filed against Caribou on December 24, 2024 with a Class Period from July 14, 2023 to July 16, 2024. Our investigation concerns whether the board of directors of Caribou have breached their fiduciary duties to the company.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=131890&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=131875&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=131845&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=131714&wire=1 or contact Joseph E. Levi, Esq.
prnewswire.com
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
See all news
